Literature DB >> 15109810

A revival of bispecific antibodies.

Peter Kufer1, Ralf Lutterbüse, Patrick A Baeuerle.   

Abstract

Mesh：

Substances：

Year:  2004        PMID： 15109810     DOI： 10.1016/j.tibtech.2004.03.006

Source DB:  PubMed          Journal:  Trends Biotechnol        ISSN： 0167-7799            Impact factor:   19.536


× No keyword cloud information.
  31 in total

Review 1.  Application of quantitative pharmacology in development of therapeutic monoclonal antibodies.

Authors:  Mohammad Tabrizi; Cherryl Funelas; Hamza Suria
Journal:  AAPS J       Date:  2010-07-24       Impact factor: 4.009

2.  Highly enhanced cytotoxicity of a dimeric bispecific diabody, the hEx3 tetrabody.

Authors:  Ryutaro Asano; Keiko Ikoma; Yukiko Sone; Hiroko Kawaguchi; Shintaro Taki; Hiroki Hayashi; Takeshi Nakanishi; Mitsuo Umetsu; Yu Katayose; Michiaki Unno; Toshio Kudo; Izumi Kumagai
Journal:  J Biol Chem       Date:  2010-05-05       Impact factor: 5.157

Review 3.  Cancer therapy with bispecific antibodies: Clinical experience.

Authors:  Archana Thakur; Lawrence G Lum
Journal:  Curr Opin Mol Ther       Date:  2010-06

4.  A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor.

Authors:  Stuart L Emanuel; Linda J Engle; Ginger Chao; Rong-Rong Zhu; Carolyn Cao; Zheng Lin; Aaron P Yamniuk; Jennifer Hosbach; Jennifer Brown; Elizabeth Fitzpatrick; Jochem Gokemeijer; Paul Morin; Brent A Morse; Irvith M Carvajal; David Fabrizio; Martin C Wright; Ruchira Das Gupta; Michael Gosselin; Daniel Cataldo; Rolf P Ryseck; Michael L Doyle; Tai W Wong; Raymond T Camphausen; Sharon T Cload; H Nicholas Marsh; Marco M Gottardis; Eric S Furfine
Journal:  MAbs       Date:  2011-01-01       Impact factor: 5.857

5.  Cytotoxic enhancement of a bispecific diabody by format conversion to tandem single-chain variable fragment (taFv): the case of the hEx3 diabody.

Authors:  Ryutaro Asano; Keiko Ikoma; Ippei Shimomura; Shintaro Taki; Takeshi Nakanishi; Mitsuo Umetsu; Izumi Kumagai
Journal:  J Biol Chem       Date:  2010-11-19       Impact factor: 5.157

Review 6.  Bispecific antibodies for cancer therapy: the light at the end of the tunnel?

Authors:  Patrick Chames; Daniel Baty
Journal:  MAbs       Date:  2009 Nov-Dec       Impact factor: 5.857

7.  Antagonistic VEGF variants engineered to simultaneously bind to and inhibit VEGFR2 and alphavbeta3 integrin.

Authors:  Niv Papo; Adam P Silverman; Jennifer L Lahti; Jennifer R Cochran
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-08       Impact factor: 11.205

8.  Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange.

Authors:  Aran F Labrijn; Joyce I Meesters; Bart E C G de Goeij; Ewald T J van den Bremer; Joost Neijssen; Muriel D van Kampen; Kristin Strumane; Sandra Verploegen; Amitava Kundu; Michael J Gramer; Patrick H C van Berkel; Jan G J van de Winkel; Janine Schuurman; Paul W H I Parren
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-11       Impact factor: 11.205

9.  Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling.

Authors:  Janet Jackman; Yongmei Chen; Arthur Huang; Barbara Moffat; Justin M Scheer; Steven R Leong; Wyne P Lee; Juan Zhang; Navneet Sharma; Yanmei Lu; Suhasini Iyer; Robert L Shields; Nancy Chiang; Michele C Bauer; Diana Wadley; Merone Roose-Girma; Richard Vandlen; Daniel G Yansura; Yan Wu; Lawren C Wu
Journal:  J Biol Chem       Date:  2010-05-05       Impact factor: 5.157

10.  Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cells.

Authors:  Ines Herrmann; Patrick A Baeuerle; Matthias Friedrich; Alexander Murr; Susanne Filusch; Dominik Rüttinger; Mariam W Majdoub; Sherven Sharma; Peter Kufer; Tobias Raum; Markus Münz
Journal:  PLoS One       Date:  2010-10-18       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.